Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Other Operating Expenses (2022 - 2025)

Lyra Therapeutics has reported Other Operating Expenses over the past 4 years, most recently at -$31000.0 for Q4 2025.

  • Quarterly results put Other Operating Expenses at -$31000.0 for Q4 2025, down 675.0% from a year ago — trailing twelve months through Dec 2025 was -$46000.0 (down 100.19% YoY), and the annual figure for FY2025 was -$31000.0, down 100.13%.
  • Other Operating Expenses for Q4 2025 was -$31000.0 at Lyra Therapeutics, down from -$15000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for LYRA hit a ceiling of $24.7 million in Q2 2024 and a floor of -$31000.0 in Q4 2025.
  • Median Other Operating Expenses over the past 4 years was $656000.0 (2022), compared with a mean of $4.6 million.
  • Biggest five-year swings in Other Operating Expenses: surged 1452.7% in 2024 and later plummeted 675.0% in 2025.
  • Lyra Therapeutics' Other Operating Expenses stood at $1.3 million in 2022, then rose by 20.97% to $1.6 million in 2023, then crashed by 100.25% to -$4000.0 in 2024, then plummeted by 675.0% to -$31000.0 in 2025.
  • The last three reported values for Other Operating Expenses were -$31000.0 (Q4 2025), -$15000.0 (Q1 2025), and -$4000.0 (Q4 2024) per Business Quant data.